Publicaciones en colaboración con investigadoras/es de Instituto de Investigación Sanitaria Biocruces Bizkaia (82)

2024

  1. Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets

    Rheumatology (United Kingdom), Vol. 63, Núm. SI, pp. SI96-SI106

  2. Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus

    Expert Review of Clinical Immunology, Vol. 20, Núm. 4, pp. 359-373

  3. Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission?

    Autoimmunity Reviews, Vol. 23, Núm. 1

  4. Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry

    Seminars in Arthritis and Rheumatism, Vol. 66

  5. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (“Registry”)

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. ANCA-associated pulmonary-renal syndrome treated with cyclophosphamide, rituximab, repeated methyl-prednisolone pulses and a reduced oral glucocorticoid regime: an observational study

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 928-935

  2. Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome

    Journal of Translational Medicine, Vol. 21, Núm. 1

  3. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 75, Núm. 5, pp. 998-1006

  4. Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study

    Autoimmunity Reviews, Vol. 22, Núm. 6

  5. Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies

    Seminars in Arthritis and Rheumatism, Vol. 59

  6. Letter to the editor: Gwinnutt JM, Toyoda T, Barraclough M, Verstappen SMM, Hornberger M, MacGregor A. Cognitive impairment in the immune-mediated inflammatory diseases compared with age-matched controls: Systematic review and meta-regression

    Seminars in Arthritis and Rheumatism

  7. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 7, pp. 927-936

  8. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients

    Medicina (Kaunas, Lithuania), Vol. 59, Núm. 8

  9. Systemic lupus erythematosus and glucocorticoids: A never-ending story?

    Best Practice and Research: Clinical Rheumatology

  10. Treatment of systemic lupus erythematosus: New therapeutic options

    Revista Clinica Espanola, Vol. 223, Núm. 10, pp. 629-639

2022

  1. Brain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder?

    Journal of Translational Medicine, Vol. 20, Núm. 1

  2. Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from the Spanish national registry

    Clinical and experimental rheumatology, Vol. 40, Núm. 11, pp. 2161-2166

  3. Impact of severe infections in SLE: An observational study from the Spanish national registry

    Lupus Science and Medicine, Vol. 9, Núm. 1

  4. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 8, pp. 1143-1150

  5. Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index

    Arthritis Care and Research, Vol. 74, Núm. 4, pp. 638-647